Day 2
Location: Coral 3
As China and Asia emerge as global powerhouses in biopharma innovation, the region's influence is reshaping the industry’s dynamics. This panel will explore the rise of cutting-edge therapies, groundbreaking research, and transformative business models originating from the East. With a focus on in-licensing strategies, the emergence of new biotechs (newcos), and an increasing volume of cross-border deals, we’ll examine how these trends are driving partnerships, altering the competitive landscape, and accelerating access to innovation.
- Robert Darwin - Private Equity/Life Sciences & Healthcare Partner, Sidley Austin LLP
- Jesus Baena - BD&L Transactions Oncology Director, Novartis
- Tomas Landh - Innovation Sourcing VP, Senior Principal Scientist Search and Evaluation, Novo Nordisk
- William Pay - Venture Partner, Pappas Capital
- Nerida Scott - VP, Head of Innovation EMEA, Johnson & Johnson
Location: Coral 2
Is AI merely a buzzword or is it truly transformative? This session examines the role of AI in biotech and pharma. Explore how AI is improving the economics of R&D, addressing integration challenges and gradually reshaping drug development. Through real-world examples, gain insights into the current influence of AI and its potential long-term impact on drug discovery and the future of the life science ecosystem.
- Hubert Birner - Managing Partner, TVM Capital
- Michelle Chen - CBO, Insilico Medicine
- Nikolaus Krall - Managing Director, Exscientia GmbH
- Miha Stajdohar - CTO and Co-founder, Genialis
- Friedrich von Bohlen - CEO, Molecular Health
Location: Coral 2
In this fireside chat with Laura Lane, Head of European Investment at Lilly Ventures, we will delve into the dynamic world of biotech investment. This session will cover the importance of new science and emerging entrepreneurs, the critical role that venture capital plays in bringing innovation to patients, and how biotech companies can get that all important first meeting.
- Jo Shorthouse - Executive Editor, In Vivo
- Laura Lane - VP Lilly Ventures , European Head, Eli Lilly & Company
Location: Exhibit Hall Stage
- Marica Nobile - Director, Federchimica Assobiotec
- Luigi Naldini - Director, SR-TIGET, San Raffaele Telethon Institute for Gene Therapy
- Matteo Giovanni Della Porta - Director, Leukemia Unit, Humanitas Research Hospital
- Marco Baccanti - Director, FITT Foundation
- Marco Gorini - Head of Digital Health and Innovation, AstraZeneca
Location: Exhibit Hall Stage
Increasingly, smaller biotech companies are launching their new drugs themselves, rather than relying on large pharmaceutical companies to make this happen for them. How can they get it right the first time?
Managers of biotech companies with a drug in late-stage clinical development face a challenge: as their asset progresses well in clinical trials, they need to decide whether to license it out or market it themselves. In the European Union, the number of companies that market only a single pharmaceutical product has increased from four in 2014 to 33 in 2024. This panel will discuss the deciding factors for successfully marketing a product independently in Europe.
What are the pros and cons of launching a product oneself instead of licensing it out? Which products are better suited for out-licensing? How does the EMA support
biopharmaceutical companies that are applying for marketing authorization for a pharmaceutical product for the first time? What role does the harmonized HTA assessment procedure play in market access and reimbursement, and how can it be aligned with marketing authorization?
- Tilo Mandry - Lead International Liaison Manager, IGES Institut GmbH
- Thomas Ballotti - Scientific Officer, European Medicines Agency
- Delphine Bourdon - VP, Head of International Finance, Blueprint Medicines
- Daniel Ghyssels - VP, Commercial Europe, Immunocore
Location: Exhibit Hall Stage
The biotech industry is rapidly evolving, with new therapeutic areas and innovative funding models emerging to drive advancements in healthcare. This panel explores the interdependent ecosystem of biotechs, research collaborators, and funding models, and how they are revolutionizing the business of biotech. We examine the latest trends in therapeutic areas, including gene therapy, immunotherapy, and precision medicine, and how they are transforming drug development. We also explore the role of research collaborators, such as CROs, in driving innovation and accelerating drug development. Finally, we discuss the latest funding models, including venture capital, public-private partnerships, and crowdfunding, and how they are changing the way biotechs raise capital and bring new therapies to market. By examining the interplay between these key elements, we provide insights into the future of the biotech industry and the potential for continued innovation in healthcare.
- Will Maier - Senior Vice President, Drug Development Solutions, ICON Biotech
- Graham Mills - Principal, Abingworth LLP
- Charles Sermon - General Counsel and Business Development, Mereo BioPharma
- Tom Shepherd - CEO, Captor Therapeutics
Location: Coral 1
Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company's lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company's development pipeline also includes several early-stage programs.
- Harold Brakewood - CBO, Immuneering Corporation
Location: Coral 1
AmMax Bio ("AmMax") is a venture-backed clinical-stage oncology company focused on the development of first-in-class therapeutics to address significant unmet needs and large market potential. It was founded in 2020 out of a partnership with Amgen wherein AmMax gained an exclusive worldwide right to AMB-066. Amgen has a minority stake in AmMax.
AmMax has an experienced management that has a proven track record and collectively covers the entire spectrum of drug development and commercialization across multiple modalities. It is led by Larry Hsu, Ph.D., who founded and led the successful IPO of Impax Laboratories on the NASDAQ with over $3 billion in market cap.
Leveraging its translational science expertise and clinical development experience, AmMax has built a robust portfolio. At the core of its portfolio are AMB-066, in Phase 2, for colorectal cancer minimal residual disease (CRC MRD) and AMB-104, an antibody-drug conjugate (ADC), for acute myeloid leukemia (AML) and solid tumors.
AMB-066 has the potential to be the first-to-market treatment for CRC MRD, an indication representing potentially a $6 billion market in the US and 5EU. CRC MRD is diagnosed by positive ctDNA and the lack of radiographic evidence of tumor in patients post surgery with/without peri-operative therapies. These patients are at a much higher risk to develop metastasis, typically within 12 months, and are currently without treatment options.
AMB-104 is the only ADC in active development that targets colony stimulating factor 1 receptor (CSF1R) to address the significant unmet needs in AML. AMB-104's unique mechanism of action also renders it the potential to target a wide range of solid tumors. Even with several approved therapies, AML is poorly served: ~20-40% of newly diagnosed don't achieve CR1 and > 50% of CR1 relapse within 3 years; Significant portions of patients have no actionable biomarkers; Existing therapies in the R/R setting have limited efficacy with OS <10% at 3 years.
- Laura Zhu - CBO, AmMax Bio, Inc.
Location: Coral 1
Precirix is a private biotechnology company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies (sdAb) labelled with radiometals. Our precision radiometal sdAb platform technology allows us to rapidly and reliably generate highly precise TRT for any cancer surface target, with unparalleled tumor retention, rapid blood clearance and minimized off-target effects
- Tom Plitz - CEO, Precirix
Location: Coral 1
Tempus aims to transform precision medicine by delivering Intelligent Diagnostics, harnessing AI to elevate laboratory testing in healthcare. These diagnostics enhance accuracy by connecting lab results directly to each patient's clinical data, creating personalized insights that guide treatment options, drug recommendations, trial selections, and clinical care pathways tailored to individual patient profiles.
At the core is the Tempus Platform, which integrates an advanced technology framework with an operating system that liberates healthcare data from traditional silos, making it actionable for physicians and researchers. With one of the largest global libraries of clinical and molecular oncology data, Tempus seeks to embed AI, including generative AI, across diagnostics to support data-driven decision-making. This platform empowers healthcare professionals to provide highly personalized care, leveraging a robust dataset that informs clinical insights and optimizes patient outcomes.
Recent advancements in cloud computing, imaging technologies, large language models, and cost-efficient molecular profiling-paired with an increasingly digital healthcare ecosystem-have created a ripe environment for scaled AI implementation. Despite the availability of healthcare data, many practitioners remain limited in their ability to apply it meaningfully. Most traditional diagnostic approaches focus on isolated data points, like specific biomarkers, rather than a comprehensive, integrated clinical profile necessary for precision care.
Tempus addresses this gap by establishing seamless data channels between providers, allowing a continuous flow of information across healthcare settings. This infrastructure enables real-time data exchange, empowering diagnostic labs, life sciences, and clinical institutions to access actionable insights. The Tempus Platform is actively deployed across the U.S., primarily in oncology, and is expanding into neuropsychology, radiology, and cardiology.
- Shyam Khatau - VP, Life Sciences, Tempus AI
Location: Coral 1
FoRx Therapeutics develops innovative small molecule inhibitors that target DNA Damage Response (DDR) pathways for anti-cancer therapy. Since DNA damage is a hallmark of cancer and requires continuous repair, the company's approach is to inhibit distinct DDR proteins and deprive cancer cells of their repair capability, resulting in the cells' death.
The company's pipeline encompasses novel, first-in-class as well as differentiated, best-in-class programs for oncology indications. The lead program is a highly potent and selective PARG inhibitor, FORX-428, which is being evaluated in IND enabling studies. The company is currently in the process of transitioning to a clinical organization and has recruited a CMO to advance FORX-428 through clinical studies.
FoRx Therapeutics has 15 employees and is backed by EQT Life Sciences (formerly LSP), M Ventures, Omega Funds, Novartis Venture Fund and Pfizer Ventures, having raised a total of 30 million CHF in Seed Financing and 10 million CHF in Bridge Financing.
- Tarig Bashir - CEO, FoRx Therapeutics AG
Location: Coral 1
Graph Therapeutics (Graph) is an AI-driven precision immunology startup developing a unique target validation platform that integrates multi-modal ex vivo perturbation screening with matched molecular profiling in primary patient samples. Our platform addresses a critical bottleneck in immune disease drug development - the lack of robust, clinically realistic target validation prior to expensive asset development. By bringing forward key elements of translational validation to the discovery phase, we can significantly reduce the current ~90% failure rate of clinical trials.
Our approach uniquely combines functional validation through siRNA knockdowns in disease-relevant primary cell models with matched multi-modal profiling at single-cell resolution, capturing morphology, transcriptomics, and protein expression in the same cells. This is integrated with clinical benchmarking through systematic comparison to standard of care drug responses in a lab-in-the-loop framework that continuously incorporates validation data to improve target predictions.
Graph builds on a decade of experience pioneering similar approaches in oncology, including development of the only ex vivo precision medicine platform validated through prospective interventional trials. We are currently funded by leading deep tech investors including Merantix Ventures, having raised €3.1M in pre-seed. Graph is actively developing core target validation capabilities alongside our sterile inflammation discovery program, positioning us to rapidly validate novel therapeutic targets as they emerge from our platform. Our goal is to build the industry's most comprehensive validation stack for immune disease targets, enabling better and faster therapeutic development for millions of patients with immune-mediated diseases.
- Gregory Vladimer - Co-Founder and CEO, Graph Therapeutics
Location: Coral 1
ImmunOs Therapeutics AG has developed a proprietary human leukocyte antigen (HLA)-based platform to generate a novel class of biologic therapeutics for the treatment of cancer and autoimmune disease.
Its lead asset IOS-1002 is in Phase I clinical trial in solid cancer.
ImmunOs is backed by an international consortium of top-tier investors, including Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and Doublepoint Ventures.
- Hilmar Ebersbach - CSO, Immunos Therapeutics
Location: Coral 1
IO Biotech is transforming the treatment of cancer patients through the discovery and development of novel immune-modulating therapeutic vaccines, including the most clinically advanced therapeutic cancer vaccine program in development for 1st line patients with advanced melanoma
Corporate Positioning Statement:
Founded in 2014, IO Biotech (Nasdaq: IOBT) is a clinical-stage biopharmaceutical company dedicated to transforming the lives of cancer patients through novel therapeutic vaccines. IO Biotech is developing immune-modulating vaccines that turn the tumor microenvironment hostile to cancer and immune-suppressive cells. Early data suggests that these vaccines have the potential to improve patient outcomes without adding systemic toxicity.
IO Biotech's lead candidate, IO102-IO103, is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the TME by stimulating activation and expansion of T cells against IDO+ and PD-L1+ cells. IO102-IO103 is currently in a pivotal Phase 3 trial for advanced melanoma, with the primary endpoint expected to read out in the first half of 2025, and in Phase 2 trials for other advanced solid tumors and for resectable solid tumors. The U.S. Food and Drug Administration granted IO102-IO103 a breakthrough therapy designation for the treatment of advanced melanoma in combination with pembrolizumab in 2020.
The company is headquartered in Copenhagen, Denmark with U.S. headquarters in New York.
- Faical Miyara - CBO, IO Biotech
Location: Coral 1
Oncolys aims to contribute to the advancement of medical science, by bringing innovation to the existing treatments for "cancer" and "serious infectious diseases", leveraging our virology-based new drug discovery technologies.
Especially in the oncology area, Oncolys develops OBP-301(Telomelysin). OBP-301 is a gene-modified oncolytic adenovirus in which selectively replicate in cancer cells by introducing human telomerase reverse transcriptase (hTERT) promotor. Oncolytic adenovirus has much potential for cancer immunotherapy because its viral replication is highly immunogenic, and oncolysis induced by such virus releases tumor antigen and provides costimulatory danger signals. From the result of phase 1 clinical study in the US, Telomelysin showed abscopal effect, which non-injected tumor as well as injected tumor was regressed in melanoma patients after single injection into one single tumor and found that not only increasing infiltration of CD8 and antigen presenting cells but diminishing Treg cells in injected tumor site.
Oncolys BioPharma has completed a pivotal study of OBP-301 in Japan in Esophageal cancer combination with RT, and planning NDA in 4Q2024-1Q2025 (JP). OBP-301 clinical trials are also ongoing for Head and neck cancer, TNBC, and HCC.
Oncolys USA our fully owned subsidiary, was established in 2016 and plays a crucial role in expanding our reach within the US market, facilitating clinical trials and fostering collaborations within leading research institution. Oncolys USA is conducting several early phase I/II studies in Esophageal cancer Gastric cancer and is planning to initiate pivotal phase 2/3 study in esophageal cancer as first indication for approval in the US. In addition, Oncolys USA is planning on expanding the label of OBP-301 in the US to Head and Neck cancer and TNBC. Oncolys USA will have exclusive rights for OBP-301 and our second-generation oncolytic virus, OBP-702 within 2025
- Talia Biran - President, Oncolys BioPharma
Location: Coral 1
Altevax is a French clinical-stage biotechnology company pioneering first-in-class immunotherapies using synthetic melanin to create biological nanoparticles that carry specific antigens. This innovative approach induces a robust and targeted immune response against tumors. Altevax's lead program focuses on glioblastoma (GBM), with a First-in-Human trial launched in November 2024.
Our proprietary technology serves as a versatile vaccine platform with potential applications across a wide range of cancers. Preclinical proof-of-concept studies have demonstrated the platform's efficacy in multiple animal models. By leveraging synthetic melanin as a carrier, Altevax enhances antigen presentation to the immune system, effectively activating T lymphocytes for a specific anti-tumor response.
Altevax targets TERT, an antigen highly expressed in glioblastoma cancer cells. The melanin-TERT nanoparticle vaccine stimulates a strong immune response, addressing the challenges posed by weakly immunogenic self-antigens by incorporating them into the melanin nanoparticle.
Altevax's proprietary platform represents a groundbreaking advancement in cancer immunotherapy. With its potential to address high unmet medical needs, this novel approach offers new hope for transforming treatment paradigms and improving outcomes for cancer patients.
- Batoul Farhat - Head of Business Development, Altevax
Location: Exhibit Hall Stage
Break, breathe, and thrive!
Take a break from your busy schedule to recharge and rejuvenate by immersing yourself in moments of tranquility and self-care.
These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.
Open to all, without prerequisites.
Sustainability Focus Area: Social Responsibility
Location: Coral 3
Join leading pharma and venture investors and unravel strategies for navigating the current dealmaking landscape. Uncover trends, actionable insights, and key considerations for building successful partnerships, along with the tools to thrive in today’s competitive environment to drive impactful collaborations.
- Evonne Sepsis - Founder and Managing Director, ESC Advisors
- Anton Gueth - Managing Director, EVOLUTION Life Science Partners
- Hakan Goker - Managing Director, M Ventures
- Jenny Laird - VP Search & Evaluation, Eli Lilly and Company
- Monika Vnuk - SVP, Global Partnering & Business Development, Sanofi
Location: Coral 2
The journey from concept to company is both exhilarating and challenging in the biotech industry, where innovation and investment intersect. This session will spotlight proven expertise in fostering groundbreaking biotech startups and Biovelocita, the first Pan-European investment strategy dedicated to accelerating biotech company creation. Industry leaders will discuss the critical ingredients for success, from identifying transformative science to scaling ventures across Europe. With insights into navigating early-stage challenges, securing funding, and driving innovation, this panel will provide a roadmap for translating bold ideas into thriving companies that redefine the future of healthcare.
- Gabriella Camboni - Partner, Sofinnova Partners
- Daniela Bellomo - Director of Business Development Division, Ospedale San Raffaele
- Celine Bouquet - Business Development Neuroscience, Ophthalmology and Rare Diseases, Roche
- Robin Carr - CEO, MyricxBio
Location: Exhibit Hall Stage
This session focuses on how to communicate with pharmaceutical regulators about the use of digital health technologies in pivotal trials of drugs and biologics.
- Steve Berman - Deputy VP, Science and Regulatory Affairs Strategy, Biotechnology Innovation Organization (BIO)
Location: Coral 3
Explore the advancing oncology landscape, with its multiple innovation areas and partnerships. Delve into the emerging therapies, latest breakthroughs in precision medicine and recent deals, along with addressing the shortcomings, enabling to redefine the future of cancer treatment.
- Linda Pullan - Business Development Consultant, founder, Pullan Consulting
- Khatereh Ahmadi - Head of Search and Evaluation Team, European BD&L Hub, MSD
- Fabrizio Calisti - Medical Director, Angelini Ventures
- Anu Connor - VP, Head of Oncology External Innovation, IPSEN
- Catherine Pickering - CEO, iOnctura
Location: Coral 3
As Pharma reshapes its pipelines to keep pace with market needs and scientific breakthroughs, venture capitalists play a pivotal role in identifying the next wave of transformative therapies. Drawing inspiration from Milan's legacy of trendsetting in fashion and art, this panel explores how VCs forecast what Pharma will need in five years' time. What defines game-changing science, and how can investors distinguish the breakthroughs that will set the future stage? Panelists will share their strategies for search and evaluation, reveal what truly stands out to Pharma, and discuss how aligning innovation with Pharma's evolving priorities can create a lasting impact. Join us for a forward-looking conversation on how to set the stage for a future that defines the industry.
- Mike Ward - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate
- Vanessa Carle - Senior Associate, Forbion
- Edward Hodgkin - Managing Partner, Syncona
- Fiona McLaughlin - Senior Director, Johnson & Johnson
Location: Exhibit Hall Stage
The European biotech sector stands at a pivotal moment, balancing groundbreaking innovation with persistent financing challenges. Despite thriving advancements in therapeutics, diagnostics, and platform technologies, securing capital—especially during the critical "valley of death" between early-stage R&D and commercialization—remains a significant hurdle. Recent discussions on global biotech financing trends have highlighted the cautious IPO market in Europe and the evolving priorities of venture capitalists and pharmaceutical companies. However, equity financing is not the only available option. Venture debt has emerged as a crucial non-dilutive funding mechanism, enabling biotech companies to extend cash runways, achieve key clinical milestones, and navigate funding gaps between equity rounds. As the sector seeks sustainable growth, strategic deployment of venture debt may prove essential in bridging financial shortfalls and accelerating innovation.
- Mike Ward - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate
- Gergely Krajcsi - Senior Investment Officer for Life Science & Biotech Growth Finance & Venture Debt, European Investment Bank
Location: Exhibit Hall Stage
Discover how your organisation can benefit from partnering with Australia’s world-leading clinical trial ecosystem.
Sector leaders will discuss why Australia is the international home of high-quality, efficient, cost-effective clinical trials.
The panel will outline Australia’s efficient approvals process, IND-free regulatory framework, world-class clinical workforce and facilities, high-quality FDA and EMA recognised data outputs, genetically diverse participant recruitment pool, robust IP protections, and generous R&D tax incentives.
- Libby Kruse - Trade Manager, Health and Life Sciences, The State Government of Victoria Australia
- Angela Luttick - EVP, Commercial, 360biolabs
- Pavel Reddy - Director, GLOBAL R&D
- Megan Robertson - Director of Research, St Vincent's Hospital Melbourne
- Sam Vohra - Founder & CEO, AVION Full Service CRO & Imaging Specialists
Location: Exhibit Hall Stage
An update on the progress of the working group for the internationalization of the biotech industry. The seminar will cover Italian programs and strategies to enhance the national Life Sciences and Biotech ecosystem globally, with a strong focus on attracting investments.
- Matteo Picariello Signori - Head of the Global Startup Program, ICE Milano
- Anna Lambiase - Chairwomen, CDP Venture Capital SGR SpA
- Massimo Carnelos - Head of Technological Innovation and Startups, Italian Ministry of Foreign Affairs and International Cooperation
- Pierluigi Paracchi - CEO of Genenta Science, Moderator of the National Working Table for the Internationalization of the Biotechnology Sector, and Member of the Executive Committee of Assobiotec, Assobiotec
- Maria Cristina Porta - Director General, ENEA Tech and Biotech Foundation
- Luca Durante - Manager of Technology Promotion Office, Italian Trade Agency
Location: Coral 2
The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies. This live competition will give a group of hand selected startups the opportunity to pitch in front of the BIO-Europe Spring audience. A panel of esteemed judges will evaluate the pitches and select the winners.
Startup Finalists: *Presenting in order
CereCura Nanotherapeutics: CNS/Neurology
Inverna Therapeutics: Rare & Orphan Diseases
MediSieve: Cell & Gene Therapies
BlackfinBio Ltd: CNS/Neurology
Dimer Pharmaceuticals: Oncology
Cycuria Therapeutics GmbH: Oncology
HHC Medical: Cell & Gene Therapies
STAb Therapeutics: Cell & Gene Therapies
- Andre Albergaria - Principal, Biovance Capital
- Jason Mellad - Co-Founder, Start Codon
- Natalia Novac - CEO & Chairwoman, Phialogics
- Giovanni Rizzo - Partner Biotech Fund, Indaco Venture Partners
- Louis-Philippe Bernier - CEO, CereCura Nanotherapeutics
- Poul Sorensen - CEO, Inverna therapeutics
- George Frodsham - Founder & CEO, MediSieve
- Peter Nolan - CEO, BlackfinBio Ltd
- Rakhee Ganti - Founder and CEO, Dimer Pharmaceuticals
- Nisit Khandelwal - CEO, Cycuria Therapeutics GmbH
- Niels Clausen - CEO & Co-Founder, HHC Medical
- Carolina Pola - CEO, STAb Therapeutics
Location: Coral 1
Ziphius, a preclinical biotech company founded in 2019, has developed a proprietary self-amplifying RNA (saRNA) and Lipid Nanoparticle (LNP) platform, which enables higher protein/antigen expression at lower doses. This results in a more potent and longer-lasting immune response-both humoral and cellular-while enhancing safety through reduced toxicity and extended dosing intervals.
Our current pipeline showcases strategic developments in infectious diseases, rare diseases, and oncology. Having raised $43 million, we are now conducting studies in higher species as we prepare for clinical trials. With a dedicated team of 65 professionals based in Belgium and the US (New York), Ziphius is committed to developing first- and best-in-class RNA medicines.
- Damien Dessis - CBO, Ziphius NV
Location: Coral 1
Rejuvenate Biomed is an AI-enabled, clinical-stage biotech company decoding the biology of aging to develop safe, synergistic combination therapeutics that holistically address the root causes of age-related diseases. By targeting multiple disease pathways simultaneously, the company aims to provide more effective treatments that can alter the course of disease. Utilizing two clinically validated proprietary drug discovery platforms, AI-enabled in silico CombinAgeTM and in vivo CelegAgeTM, Rejuvenate Biomed has generated a robust pipeline of five unique combination drugs targeting different age-related diseases. These conditions range from neuromuscular, musculoskeletal, metabolic, neurodegenerative and immunology related indications. Its lead Phase 2 asset, RJx-01, has already demonstrated significant potential in treating sarcopenia. The company's disease agnostic drug discovery platforms continue to provide insight by uncovering hidden patterns in biomedical graphs into future therapeutics, driving pipeline growth and potential partnerships. Rejuvenate Biomed is dedicated to promoting healthy aging.
- Ann Belien - Founder and CEO, Rejuvenate Biomed
Location: Coral 1
Pioneering Medicines is Flagship's in house drug discovery and development unit. Pioneering Medicines was formed to accelerate the creation of novel therapeutics and maximize the value creation and patient impact of Flagship's first-in-category bioplatforms. We're here to make new medicines for patients, sooner.
Our team of drug development experts creates new therapeutics built from Flagship's innovative bioplatforms and novel modalities. More than 40 companies across the Flagship ecosystem are pioneering innovative platform technologies to address major challenges in human health. Pioneering Medicines explores and identifies new product concepts and then works jointly with Flagship's companies to form integrated teams that advance medicines through robust discovery and early clinical development.
Pioneering Medicines also partners with external collaborators across biopharma throughout our R&D process. We apply our unique approach to the R&D priorities of our partners through highly co-creative relationships that draw on the expertise of our respective teams. Pioneering Medicines leads Flagship's Innovation Supply Chain Partnerships with Novo Nordisk, Pfizer and GSK to speed innovation in drug development and bring novel therapies to patients. The team also leads a partnership with the Cystic Fibrosis Foundation to develop therapeutics that address the unmet needs of people living with cystic fibrosis.
- Fang Zhang - VP, Business Development, Pioneering Medicines
Location: Coral 1
Company and Financials
• Company: InnoMedica Holding AG, fully owned subsidiaries, Switzerland/Germany
• Financing: a total of 13 public capital increases, 1,555 shareholders, CHF 80m raised
• IPO: SIX Swiss Exchange or Nasdaq in 2027 after breakeven, IFRS reporting since 2019
• Current Cash burn: CHF 0.8m per month
• Cash at the end of 2024: CHF 11m
• Largest shareholder: Dr. Peter Halbherr, 18 percent
• Shareholder pool: a group of five entities with 36 percent shareholdings
• Financing needs: CHF 38m financing gap until breakeven
Technology
Newly developed lipid nanoparticle platform capable of efficient site-directed drug delivery, reaching unprecedented efficacy-toxicity profiles for existing and new molecular entities. The in-house manufacturing technology enables InnoMedica to produce a multiverse of highly functional lipid nanoparticles with the world's smallest diameter of 35 nanometers.
Clinical Assets
1. Talineuren: first-in-class clinical-stage Parkinson's disease treatment, weekly intravenous application of GM1-ganglioside in a blood-brain barrier crossing lipid nanoparticle, phase I/IIa study with significant reduction of MDS-UPDRS and no severe adverse events, a new mode of action with a strong data suggesting a disease-modifying effect on Parkinson's disease.
2. Talidox: best-in-class clinical-stage breast cancer treatment, monthly intravenous application of doxorubicin in a lipid nanoparticle, currently under review for market approval by Swissmedic, highest AUC and serum half-life of more than 120 hours, largely reduced undesired drug reactions and 70 percent disease control rate.
Intellectual Property
Strongest patent protection, latest patent: Liposomes comprising sphingomyelin US 11,607,385 B2 protecting the blood-brain barrier crossing capabilities of InnoMedica liposome technology.
For more information visit our website: www.innomedica.com
- Jonas Zeller - CFO, InnoMedica Holding AG
Location: Coral 1
Alithea Genomics is a global leader in large-scale transcriptomics for drug discovery. Our revolutionary technology, DRUG-seq, enables transcriptomic profiling of drug response at an unprecedented scale, resolution, and data output.
The DRUG-seq workflow begins directly from cell lines and organoids, eliminating the need for time-consuming RNA extraction. We use RNA barcoding to label generated lysates, allowing massively multiplexed processing of tens to thousands of 96- and 384-well plates in just one week.
Our libraries can be sequenced on all major platforms, including Illumina, Element Bioscience, and Ultima Genomics. DRUG-seq is versatile, producing data for 3'-mRNA, full-length mRNA, or total RNA (including non-coding RNA species).
Validated across numerous cell lines and applications, DRUG-seq is used in tox screening and AI-driven drug discovery. It is available as both kits and services, provided directly and exclusively by Alithea.
Alithea Genomics has a direct presence in Europe and North America, with trusted partners in China, South Korea, Japan, and Australia. During this presentation, Alithea's CEO, Riccardo Dainese, will provide an in-depth look at our technology, highlight exciting large-scale projects, and offer insight into upcoming innovations.
- Riccardo Dainese - CEO, Alithea Genomics SA
Location: Coral 1
Founded in September 2019, we are a team of experienced AI/machine learning researchers and medicinal and computational chemists applying state-of-the-art generative AI to drug discovery. We work closely with biopharmaceutical partners to redefine the unit economics of drug discovery and development.
Variational AI has developed Enki, a small molecule drug discovery foundation model. Enki is a generative AI model that has been trained on many millions of high-quality experimental data samples and delivers novel and diverse potent (nM) and selective lead-like and synthesizable structures in weeks based on a preclinical TPP.
Trusted by leading pharma and biotechs, Enki is not software. It is available on a partnering/collab basis or as a platform. Variational AI has also generated early-stage assets available for out-licensing.
- Sree Vadlamudi - EVP Business Development, VariationalAI
Location: Coral 1
NanoSyrinx is a discovery stage synthetic biology company developing Nanosyringes as a next-generation platform technology for the targeted intracellular delivery of biological molecules.
Our vision at NanoSyrinx is to unlock the interior of the cell and the myriad therapeutic opportunities within that are currently difficult (or impossible) to drug, by enabling targeted, intracellular delivery of protein therapeutics.
NanoSyrinx closed a £10m financing round in August 2024, led by M Ventures (Amsterdam), BGF (London) and Octopus Ventures (London) and supported by Eli Lilly and Company, IQ Capital (Cambridge) and Jonathan Milner (Cambridge).
- James Lapworth - CBO, NanoSyrinx Ltd
Location: Coral 1
Location: Coral 1
Location: Coral 1
AaviGen GmbH was founded in 2019 and is a pre-clinical stage biotechnology company. The company specializes in the development of transformative gene therapy medicinal products (GTMPs) for genetic and acquired cardiovascular and cardiopulmonary diseases. Utilizing a proprietary portfolio of genetically-engineered heart-specific Adeno-Associated Viruses (AAVs), AaviGen delivers therapeutic genes directly to the diseased heart cells via a single intravenous injection, with the aim of advancing safe and effective precision GTMPs for heart-related ailments. Integrating cutting-edge technologies with the interdisciplinary expertise of its founders - spanning clinical cardiology, virology and genetic vector engineering, GTMP development, health economics and regulatory affairs - AaviGen aims to address the unmet needs of millions of patients worldwide with its scalable vector platform and therapeutic pipeline, ultimately reshaping the clinical landscape of cardiovascular care.
- Marc Lerchenmüller - Managing Director and CFO, AaviGen
Location: Coral 1
Persevere Therapeutics Inc is an oncology newco launched in February 2025 to acquire the rights to a clinical stage program (misetionamide - GP-2250) from Geistlich Pharma and their subsidiary, Panavance Therapeutics.
- Greg Bosch - CEO, Persevere Therapeutics
Location: Coral 1
Precision Prevention of Women's Cancers Through Epigenetic Innovation
Vison
At Sola Dx, our vision is to drive a global transformation in women's cancer prevention and early detection. We are committed to making innovative, accessible, and personalized solutions the standard of care-empowering women worldwide to live healthier lives.
Mission
Our mission is to bridge critical gaps in women's cancer prevention and diagnosis by delivering cutting-edge epigenetic solutions. Through personalized care and global accessibility, we strive to improve health outcomes for women everywhere.
Value Proposition
We create value by revolutionising primary and secondary cancer prevention with breakthrough innovations, including the WID®-easy test for the early detection of endometrial cancer and the WID®-can test for cervical cancer risk prediction. Our unwavering dedication to innovation ensures that we address today's most pressing diagnostic needs while paving the way for a future where personalised, accessible, and effective cancer prevention becomes the global standard of care.
Uniqueness
Sola Dx stands apart as a commercial-stage epigenetic diagnostics company, built on over 30 years of pioneering research in DNA methylation and gynecological cancers. Our technologies originate from the groundbreaking work of Prof. Martin Widschwendter and his internationally recognized academic team. Leveraging state-of-the-art epigenetic science, we develop diagnostic tests that are both highly accurate and minimally invasive. By focusing on precision prevention, we empower women with the knowledge and tools to make informed health decisions-establishing ourselves as leaders in women's health diagnostics.
- Peter Kayatz - CEO, Sola Diagnostics GmbH
Location: Coral 1
CLEARA is a private, Netherlands-based preclinical-stage biotherapeutics company, with an innovative discovery pipeline focused on targeting diseases with a high unmet medical need. The company's main Discovery engine is a platform technology of creation and iterative optimization of families of stabilized, D-amino acid, Cell-Penetrating Peptides (CPPs) designed for the specific purpose of disrupting protein-protein interactions. CLEARA's CPPs are optimized for in vivo safety, pharmacokinetics and stability, making them unique over competitive approaches. The targeted proteins are considered poorly 'druggable' by small molecule targeted agents that are currently available or under development.
Location: Coral 1
Location: Exhibit hall stage
MitoRx Therapeutics is a preclinical stage first-in-class biotech developing mitochondrial-targeted small molecules in obesity-related disorders
MitoRx's novel small molecules combine strong muscle preservation activity with anti-obesogenic properties, featuring a mechanism of action differentiated from any other small molecule in the clinic or on the market. MitoRx is raising a Series A to take its approach forward through IND to a novel phase 1/2a part c in obese patients with underlying disease, with a trial design generating early non-invasive MRI imaging evidence of efficacy in muscle and liver.
In results to be presented at BIO-Europe Spring 2025, MitoRx will demonstrate that their pioneering approach restoring sulfide-signal transduction in the diet-induced obesity model drive fat loss while preserving muscles and therefore represents a new class of weight loss medicine. This avoids the relentless agonism of GLP-1 that causes gastrointestinal side effects and loss of lean mass, leading to poor compliance and cessation of therapy which blights incretin medicines, offering a safer alternative as a monotherapy in sarcopenic obesity including many T2D patients as well as patients who have ceased GLP-1 therapy.
In summary, while incretins are anti-obesogenic and cause muscle wasting, MitoRx's novel approach is anti-obesogenic and is muscle preserving.
- Jonathan Rees - CEO, MitoRx Therapeutics Limited
Location: Exhibit hall stage
ADIPONECTIN, THE PERFECT CO-AGONIST TO ENHANCE GLP-1RA THERAPEUTIC EFFECTS ON OBESITY AND DIABETES.
Ciloa has developed a breakthrough solution for obesity, diabetes, MASH and metabolic diseases based on adiponectin, renowned in particular for its anti-inflammatory, anti-oxidative stress and insulin-sensitizing properties. As a pioneer in EVs bioengineering, we have succeeded for the first time in stabilizing highly multimerized and functional adiponectin by anchoring it to EVs. In DIO/MASH animal model, this adiponectin acts synergistically with the GLP-1R agonist to stimulate weight loss, to enhance dramatically fat clearance in all organs tested and induce full recovery of insulin sensitivity, while preserving muscle mass.
In parallel, we have also overcome the challenges of biotherapeutic EV production: in 2023, we produced 20 batches of high quality bioengineered EVs in our cleanroom from over 100 liters of cell culture.
- Robert Z. Mamoun - CEO, Ciloa
Location: Exhibit hall stage
EnteroTarget ApS is a Copenhagen University spinout company that has developed and patented a 'First-in-Class' Inflammatory Bowel Disease (IBD) treatment. The company was established in 2018 after Professor Olsen and his research team made a remarkable discovery.
By re-purposing insulin and administrating this molecule locally within the bowel's, insulin receptors induce CA3 antioxidant proteins which in turn protects the epithelium cells from inflammation and allows the epithelial wall to begin restoration. As the epithelial wall is restored, inflammation is significantly reduced.
The unmet medical need for IBD is very large and growing 50% by 2030 to USD 30 Bn. This was evident by big Pharma acquiring clinical stage IBD treatments in 2023 with rich valuations. Currently, there is no cure for IBD and all existing and pipeline treatments targets the immune system, achieves a modest 30-40% improvement rate, while all patients experience a wide range of moderate to serious side-affects.
EnteroTarget's local treatment is a new and refreshing approach to IBD that has produced positive early-stage results and has demonstrated outperformance compared with existing/pipeline treatments which have used the same pre-clinical DSS models.
The re-purposing of Insulin comes with safety advantages also. The pharmacological properties are well-known compared with newly formed molecules and we have positive safety data available.
EnteroTarget is targeting three IBD indications with one indication being an orphan designated disease with two different patented products. EnteroCalm a rectal solution and EnteroShuttle a smart capsule.
- Jorgen Olsen - CEO, EnteroTarget ApS
Location: Exhibit hall stage
Alphyn is developing first-in-class therapeutics for severe and prevalent skin diseases using its unique multiple bioactive Zabalafin Multi-Target Therapeutic Drug Platform. Zabalafin Hydrogel, the company's lead candidate for atopic dermatitis (AD), is at the forefront of an evolution to treat the bacterial cause and exacerbation of the disease, in addition to directly treating the itch, inflammation, and infection that make AD so difficult to manage.
AD is a devastating chronic disease with significant impacts on quality of life. It is the most common form of eczema, with an estimated market size of $118 billion globally. Current treatments fall short on efficacy and safety for worry-free long-term and continuous use and address only the immune component of the disease. Alphyn is well positioned to enter this large and growing market with a differentiated product that addresses these shortcomings.
Zabalafin Hydrogel completed two Phase 2a clinical trials, demonstrating efficacy against both the inflammatory and bacterial components of AD, with a strong safety profile for worry-free continuous and long-term use. Clinical trial results show superiority to current commercialized therapeutics and clinical-stage pipeline candidates.
Alphyn expects a faster, less expensive regulatory approval process than competitive products. Additionally, the company has a strong 4-part market protection program including (1) patent protection through 2042 and beyond, (2) 10 years FDA regulatory market exclusivity in the U.S. and EU and 8 years' regulatory exclusivity in the EU and Japan, (3) as well as protection from generics in the US, as there is currently no generic approval path from FDA-approved generics and (4) an estimated 15 year head start protection in drug raw material supply.
With the benefits of the Zabalafin Platform, Alphyn is also advancing its second drug candidate.
- Neal Koller - CEO, Alphyn Biologics
Location: Exhibit hall stage
Swiss Rockets is dedicated to developing groundbreaking medicines that will transform the treatment of cancer, infectious diseases, and auto-immune disorders.
We strive to be at the forefront of scientific discovery and clinical excellence, continuously pushing the boundaries of medical knowledge to address unmet medical needs. Through innovation and collaboration, we aim to build a thriving ecosystem that supports cutting-edge technologies and empowers inventors to turn their bold ideas into life-changing therapies.
Our ultimate goal is to improve global health outcomes and be a leader in the biotech industry.
- Andreas Emmenegger - CFO and CBO, Swiss Rockets AG
Location: Exhibit hall stage
Eleva is a clinical-stage biopharma company that strives to bring novel therapies to patients in need. Partnerships are at the heart of our strategy and our unique moss-based platform and capabilities can unlock a range of 1st- and best-in-class biologics.
We are currently advancing two proprietary clinical programs, which have the potential to change the life of patients affected from complement-related disorders and Fabry disease. Moreover, Eleva is looking to expand its pipeline with innovative compounds that will profit from its technology and expertise such as complex proteins, enzymes, cytokines and cytokine-fusion molecules, and various therapeutic antibody formats.
CPV-104 (recombinant human complement factor H; CFH) is a natural regulator of the C3 amplification loop. We demonstrated that CPV-104 can restore complement homeostasis without blocking the complement system's protective function. In contrast to other approaches, patients treated with CPV-104 are therefore not exposed to a higher risk of infection. We have validated the program's potential in indications with high unmet needs such as PNH, C3G, aHUS, dry AMD and ANCA vasculitis. A CTA to commence clinical studies in C3G was filed in Q4/2024 and the program has received ODD status. Our moss-based platform provides access to recombinant Factor H in previously unmet quantity and quality.
RPV-001 (recombinant and glylco-optimized human α-Galactosidase; aGal) addresses the key disease-relevant pathway and deficiency in Fabry disease. Eleva's moss-based RPV-001 features favorable human-like glycosylation thereby driving cell uptake via the natural mannose receptor for significantly improved lysosomal deposition and organ distribution. As a result, RPV-001 has demonstrated safety and a more lasting reduction of Gb3 levels, a key clinical biomarker, up to 28 days post infusion in a clinical Phase 1b study. We are currently evaluating partnership structures to advance the program towards market approval.
- Henrik Luessen - CBO, Eleva GmbH
Location: Exhibit hall stage
Ananda Scientific is a research driven biotech company developing life changing medicines to transform neuropsychiatric health. Our lead program is focused on PTSD - a chronic disease with high unmet need requiring lifelong treatment Our two well powered phase-2 PTSD clinical trials (N=120 &140) are nearing completion at high quality academic sites. We are in early discussions with FDA to initiate a phase-3 PTSD trial by the end of 2025. Through a patented drug delivery technology developed at Hebrew University in Jerusalem, we have overcome the primary challenge with CBD delivery i.e. poor absorption and inconsistent uptake. This unique and proprietary delivery technology allows us to unmask the true potential of CBD which was demonstrated in an NIH funded Phase-1 PK study done head-to-head against Epidiolex®. The company is working on six phase-2 trials for multiple neuropsychiatric indications including PTSD, Opioid Use Disorder, Social Anxiety and Smoking Cessation. We have a strong patent estate covering global markets in 35+ countries and have built a GxP compliant drug development infrastructure with an experienced team capable to move multiple indications for FDA approval.
Location: Exhibit hall stage
Verdant Scientific is a preclinical stage pharma startup developing a first-in-class, first-in-approach small molecule (VDT-002) for the treatment of atopic dermatitis (AD), more commonly known as eczema. AD is a chronic inflammatory skin condition which significantly impacts the lives of more than 220M people worldwide. There is no cure for the condition, and current treatments seek only to reduce the symptoms of the disease by modulating the body's immune response. Current treatment options are insufficient, with over 55% of AD patients reporting inadequate disease control. Verdant's approach to treating AD is completely different than current therapeutics - we are the first to target the primary driver of the signs and symptoms of the disease: the staphylococcus aureus bacteria which colonize AD patients' skin. It is widely known and has been extensively demonstrated in peer reviewed literature that s. aureus produces toxins that directly destroy the skin barrier and also induce pruritus, or itching. S. aureus bacteria only produce significant toxins when detect that they are in sufficient numbers. Our API stops the bacteria from being able to communicate, which effectively tricks them into thinking they are alone, and in turn stops the bacteria from producing the toxins that drive AD symptoms. Our elegant mechanism of action does not kill the bacteria, but rather stops them from causing harm, thereby not inducing selective pressure that could lead to resistance. This fact opens the door for VDT-002 being used in perpetuity in a prophylactic manner, preventing the signs and symptoms of the disease - in other words, a potential "cure" for many AD patients. Because of this and our likely safety profile, VDT-002 stands poised to usher in a paradigm shift in AD treatment, and to become a significant blockbuster drug in the process.
Location: Exhibit Hall Stage
Break, breathe, and thrive!
Take a break from your busy schedule to recharge and rejuvenate by immersing yourself in moments of tranquility and self-care.
These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.
Open to all, without prerequisites.
Sustainability Focus Area: Social Responsibility